Grigoriadis, Kristiana http://orcid.org/0000-0002-8435-0176
Huebner, Ariana http://orcid.org/0000-0001-8009-4999
Bunkum, Abigail http://orcid.org/0000-0002-7753-9421
Colliver, Emma http://orcid.org/0000-0002-1497-0740
Frankell, Alexander M. http://orcid.org/0000-0002-0341-7878
Hill, Mark S.
Thol, Kerstin http://orcid.org/0000-0002-4624-118X
Birkbak, Nicolai J. http://orcid.org/0000-0003-1613-9587
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Zaccaria, Simone http://orcid.org/0000-0002-5265-7392
McGranahan, Nicholas http://orcid.org/0000-0001-9537-4045
Funding for this research was provided by:
Cancer Research UK Lung Cancer Centre of Excellence, CRUK City of London Centre Award
Francis Crick Institute
Cancer Research UK (CC2041)
Article History
Received: 11 January 2023
Accepted: 24 August 2023
First Online: 28 November 2023
Competing interests
: A.M.F. is co-inventor to a patent application to determine methods and systems for tumor monitoring (PCT/EP2022/077987). N.J.B. is a co-inventor to a patent to identify responders to cancer treatment (PCT/GB2018/051912) and a co-inventor on a patent for methods for predicting anti-cancer response (US14/466,208). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx Inc—collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical, and Personalis. He is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s Scientific Advisory Board. He receives consultant fees from Achilles Therapeutics (also a Scientific Advisory Board member), Bicycle Therapeutics (also a Scientific Advisory Board member), Genentech, Medicxi, China Innovation Centre of Roche (CICoR) formerly Roche Innovation Centre–Shanghai, Metabomed (until July 2022) and the Sarah Cannon Research Institute. He has received honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina, and Roche-Ventana; had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. is listed as an inventor on a European patent application relating to assay technology to detect tumor recurrence (PCT/GB2017/053289), which has been licensed to commercial entities and, under his terms of employment, C.S. is due a revenue share of any revenue generated from such license(s). C.S. holds patents relating to targeting neoantigens (PCT/EP2016/059401), to identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), to determining human leukocyte antigen loss of heterozygosity (HLA LOH) (PCT/GB2018/052004), to predicting survival rates of patients with cancer (PCT/GB2020/050221), to identifying patients who respond to cancer treatment (PCT/GB2018/051912), to detecting tumor mutations (US patent: PCT/US2017/28013) and to methods for lung cancer detection (US20190106751A1). He also holds both a European and US patent related to identifying indel targets (PCT/GB2018/051892) and is co-inventor to a patent application to determine methods and systems for tumor monitoring (PCT/EP2022/077987) and is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221).